Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
Addiction. 2024 Nov;119(11):1987-1997. doi: 10.1111/add.16622. Epub 2024 Jul 31.
To estimate the strength of association between psychiatric disorders and substance use disorders (SUD), and cannabis use and cannabis use disorder (CUD) during early pregnancy.
Observational study.
Kaiser Permanente Northern California, USA.
299 496 pregnancies from 227 555 individuals screened for cannabis use by self-report and a urine toxicology test at entrance to prenatal care in Kaiser Permanente Northern California during January 2011-December 2021 (excepting year 2020). The sample was 62.5% non-White, with a mean (standard deviation) age of 31.1 (5.5) years; 6.8% used cannabis; 0.2% had a CUD.
Exposure variables included electronic health record-based psychiatric diagnoses of attention deficit hyperactivity, anxiety, bipolar, depressive, personality, posttraumatic stress and psychotic disorders; and alcohol, opioid, stimulant and tobacco use disorders, during the two years prior to pregnancy up to the day before the prenatal substance use screening date. Outcome variables were any cannabis use, frequency of self-reported cannabis use and CUD during early pregnancy.
Psychiatric disorder prevalence ranged from 0.2% (psychotic) to 14.3% (anxiety), and SUD ranged from 0.3% (stimulant/opioid) to 3.8% (tobacco). Psychiatric disorders were associated with cannabis use and CUD, with the strongest association for any use found for bipolar disorder (adjusted odds ratio [aOR] = 2.83; 95% confidence interval [CI] = 2.53-3.17) and the strongest association for CUD found for psychotic disorders (aOR = 10.01, 95% CI = 6.52-15.37). SUDs were associated with cannabis use and CUD, with the strongest association for any use found for tobacco use disorder (aOR = 4.03, 95% CI = 3.82-4.24) and the strongest association for CUD found for stimulant use disorder (aOR = 21.99, 95% CI = 16.53-29.26). Anxiety, bipolar, depressive disorders and tobacco use disorder were associated with greater odds of daily than monthly or less cannabis use.
Psychiatric disorders and substance use disorders appear to be associated with elevated odds of any and frequent cannabis use as well as cannabis use disorder during early pregnancy. In most cases, the associations with cannabis outcomes were stronger for substance use disorders than other psychiatric disorders.
评估精神障碍与物质使用障碍(SUD)之间的关联强度,以及妊娠早期的大麻使用与大麻使用障碍(CUD)。
观察性研究。
美国北加州凯撒永久医疗集团。
2011 年 1 月至 2021 年 12 月期间,在北加州凯撒永久医疗集团接受产前护理时,通过自我报告和尿液毒理学测试筛查大麻使用者的 227555 名个体中的 299496 例妊娠,除外 2020 年。该样本中 62.5%是非白人,平均(标准差)年龄为 31.1(5.5)岁;6.8%使用大麻;0.2%患有 CUD。
暴露变量包括电子健康记录中诊断的注意力缺陷多动、焦虑、双相、抑郁、人格、创伤后应激和精神病性障碍;以及妊娠前两年至产前物质使用筛查日期前一天的酒精、阿片类药物、兴奋剂和烟草使用障碍。结局变量为妊娠早期任何大麻使用、自我报告的大麻使用频率和 CUD。
精神障碍的患病率从 0.2%(精神病性)到 14.3%(焦虑)不等,物质使用障碍的患病率从 0.3%(兴奋剂/阿片类)到 3.8%(烟草)不等。精神障碍与大麻使用和 CUD 相关,其中双相障碍的任何使用关联最强(调整后的优势比[aOR] = 2.83;95%置信区间[CI] = 2.53-3.17),精神病性障碍的 CUD 关联最强(aOR = 10.01,95% CI = 6.52-15.37)。物质使用障碍与大麻使用和 CUD 相关,其中烟草使用障碍的任何使用关联最强(aOR = 4.03,95% CI = 3.82-4.24),兴奋剂使用障碍的 CUD 关联最强(aOR = 21.99,95% CI = 16.53-29.26)。焦虑、双相、抑郁障碍和烟草使用障碍与每日使用大麻而非每月或更少使用大麻的几率更高相关。
精神障碍和物质使用障碍似乎与妊娠早期任何和频繁使用大麻以及大麻使用障碍的几率增加有关。在大多数情况下,与大麻结局的关联在物质使用障碍方面比其他精神障碍更强。